Arkin Bio-Ventures

About Arkin Bio-Ventures

Arkin Bio-Ventures is a versatile investment fund focusing on life sciences among several other sectors. Specifically, they take a strong interest in the pharmaceutical industry and support innovative early to mid-stage companies. Their investment sphere covers a variety of medical and healthcare segments, such as immunotherapy, cancer, metabolism, microbiome, CNS (central nervous system), autoimmune diseases, orphan diseases, and drug delivery platforms. As a multi-asset manager with over $2 billion under management, they operate across VC (venture capital), PE (private equity), and Hedge Funds, leveraging their resources to make impactful investments in health technologies, including early to late-stage biotech firms, digital health startups, and public pharmaceutical companies. Arkin Bio-Ventures aims to accelerate the development of life-changing therapies and contribute to the future of healthcare. They manage multiple capital pools which gives them the flexibility to seize diverse opportunities in the market. Through their various investment arms—Arkin Health, Arkin Equity, Arkin Tech, and Arkin Real Estate—they demonstrate not only a robust presence in health technologies but also in areas such as digital forensics, food technology, sustainable energy, cloud solutions, consumer finance, and global real estate. Arkin Bio-Ventures has made over 30 notable investments, including in companies like Digital Ocean, Lendbuzz, and HoneyBook. Some highlighted portfolio companies include Keros Therapeutics, HI-Bio, Eleos, Laguna, and Cellebrite. The firm's approach is comprehensive and includes involvement in properties like student housing, multi-family investments, and high-yield industrial and logistics properties. Arkin Bio-Ventures prides itself on its experienced team of investment experts and seeks to be ahead of the curve by staying informed about the latest industry news and trends.